Boehringer Ingelheim takes rare kidney disease drug to Phase 3 despite puzzling mid-stage data

Boehringer Ingelheim’s experimental pill has shown signs of improving kidney function in patients with a rare renal condition in a mid-stage trial. But the data are somewhat confusing, with the lowest dose working better than ...